FRZB Identified as Regulator of Angiogenesis Through Caveolin-1-Mediated TGFβ Pathways

A recent study has identified a previously unknown mechanism by which the protein FRZB inhibits angiogenesis, the process of new blood vessel formation. Researchers led by Chen CJ have demonstrated that FRZB achieves this effect through Caveolin-1-mediated TGFβ signaling pathways. The findings, published in *Nature Communications* in 2026, provide new insights into vascular biology and may inform future approaches to treating diseases linked to abnormal blood vessel growth.

The study highlights the complex molecular interactions involved in FRZB’s anti-angiogenic activity. Specifically, researchers found that FRZB regulates angiogenesis by influencing Caveolin-1, a key structural protein involved in cellular signaling, which in turn modulates TGFβ (Transforming Growth Factor Beta) pathways. These pathways play a critical role in controlling cell behavior during blood vessel formation. The research underscores the potential significance of these mechanisms for understanding disease progression and developing therapeutic strategies targeting abnormal vascular growth.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: April 7, 2026

Author

GOAI